Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MSH6 (MutS homolog 6)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

MSH6 mutation	Gastric Cancer	MSH6 mutation	Gastric Cancer	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2
MSH6 mutation	Gastric Cancer	MSH6 mutation	Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
MSH6 mutation	Colorectal Cancer	MSH6 mutation	Colorectal Cancer	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials 5-fluorouracil + oxaliplatin Resistant : C3	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials 5-fluorouracil + oxaliplatin Resistant : C3
MSH6 mutation	Triple Negative Breast Cancer	MSH6 mutation	Triple Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
MSH6 T1219I	Colorectal Cancer	MSH6 T1219I	Colorectal Cancer	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
MSH2 deletion + MSH6 deletion	Endometrial Cancer	MSH2 deletion + MSH6 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MSH6 rs3136228	Lung Cancer	MSH6 rs3136228	Lung Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
MSH2 deletion + MSH6 deletion	Rectal Cancer	MSH2 deletion + MSH6 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSH6 mutation	Rectal Cancer	MSH6 mutation	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSH6 mutation + MLH1 mutation + MSI-H	Squamous Cell Skin Cancer	MSH6 mutation + MLH1 mutation + MSI-H	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma	MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4
MSI-H + MSH2 expression + MSH6 expression	Prostate Cancer	MSI-H + MSH2 expression + MSH6 expression	Prostate Cancer	docetaxel Sensitive: C4 – Case Studies docetaxel Sensitive : C4	docetaxel Sensitive: C4 – Case Studies docetaxel Sensitive : C4
MSH6 F1088fs	Endometrial Adenocarcinoma	MSH6 F1088fs	Endometrial Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH6 mutation	Endometrial Cancer	MSH6 mutation	Endometrial Cancer	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
MSH6 deletion	Urothelial Cancer	MSH6 deletion	Urothelial Cancer	durvalumab + MEDI0680 Sensitive: C4 – Case Studies durvalumab + MEDI0680 Sensitive : C4	durvalumab + MEDI0680 Sensitive: C4 – Case Studies durvalumab + MEDI0680 Sensitive : C4
MSH6 mutation	Breast Cancer	MSH6 mutation	Breast Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH2 negative + MSH6 negative	Prostate Cancer	MSH2 negative + MSH6 negative	Prostate Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH2 mutation + MSH6 mutation	Prostate Cancer	MSH2 mutation + MSH6 mutation	Prostate Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4
MSH2 mutation + MSH6 mutation + BRCA1 mutation	Prostate Cancer	MSH2 mutation + MSH6 mutation + BRCA1 mutation	Prostate Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4
TMB-H + MSH6 F1088fs	Ovarian Serous Adenocarcinoma	TMB-H + MSH6 F1088fs	Ovarian Serous Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH6 mutation	Germ Cell Tumors	MSH6 mutation	Germ Cell Tumors	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4